Onglyza (saxagliptin) is a DPP-4 inhibitor developed by Astrazeneca and approved by the U.S. Food and Drug Administration in 2009.

While hailed as an effective drug-class to combat type 2 diabetes, the FDA has discovered that many DPP-4 inhibitors, including Onglyza, can often heighten the risk of consumers developing pancreatic cancer, or heart attacks. This discovery has been validated by multiple medical studies that have discovered three previously undisclosed Onglyza health risks, including heart attacks.

Safety Communication Onglyza Medical Data  
Risk of Pancreatic Cancer – 2013 JAMA Internal Medicine – 2013
Risk of Joint Pain – 2015 NCBI – 2012
   Risk of Heart Failure – 2016 NMCD – 2014


Is Pancreatic Cancer A Side Effect Of Onglyza?

As can be seen from the table above, several dangerous side effects of Onglyza that were previously undisclosed have been discovered in recent years.

Of these discovered side effects, the existence of a heightened pancreatic cancer risk has come as the most disturbing.

While AstraZeneca may dispute the connection between their drug and pancreatic cancer, several studies published before and after an FDA safety communication in 2013 provide substantial evidence that the claim of a Onglyza-pancreatic cancer connection is valid.

In addition to confirming studies, the FDA has fielded multiple reports from Onglyza users alleging the development of pancreatic cancer as a result of taking the drug.

As time passes, it is expected that additional studies will once again confirm that there is a connection between Onglyza use and pancreatic cancer development.

Additionally, an increase in consumer reports of pancreatic cancer development will offer even more confirmation to the already strong claim.

How Dangerous Is Onglyza Related To Pancreatic Cancer?

The most troubling aspect of the pancreatic cancer-Onglyza discovery is the deadly nature of pancreatic cancer.

Pancreatic cancer is often cited as the single deadliest form of cancer due to frequent inability to detect in its early stages.

While different cancer types including prostate and breast cancer generally have a 5-year survivability rate ranging from 22% to 100% depending on when detected, pancreatic cancer is associated with a range between 1% and 14% depending on stage of discovery.

With the deadly nature of pancreatic cancer, the ability of Onglyza to heighten a consumers risk of developing it presents a risk for the consumer as well as their loved ones.

While pancreatic cancer is difficult to detect in initial stages, commonly cited symptoms include:

  • Jaundice (Yellow Skin)
  • Blood Clots
  • Upper Abdominal Pain
  • Depression
  • Loss of Appetite
  • Weight Loss

Due to the nature of this cancer, if any of these symptoms are identified you must contact a medical professional without delay.

DPP-4 inhibitors are relatively new as they were first brought to market in 2006. With information relating to their connection to pancreatic cancer still being discovered, the full extent of the pancreatic cancer-Onglyza connection may not be known for years.

Has Onglyza Been Recalled By The U.S. Food and Drug Administration?

As of June 3, 2016, the FDA has yet to issue an Onglyza recall and it appears unlikely that AstraZeneca will self-enforce a recall of this dangerous drug.

Current analysis is unclear as to whether a recall will occur or what time-frame it could encompass.

Victims are still eligible to file lawsuits against AstraZeneca though, and should do so if they were victims.

Our Onglyza Lawyers Can Help

Our dangerous prescription drug lawyers can help if you or a loved one has been harmed after taking Onglyza. Lawsuits are being investigated for serious complications that have caused pain and suffering in many patients. You may be entitled to a settlement.

We do not charge any legal fees unless we win your case, and we will pay for all case costs and litigation expenses. If your claim in not successful for any reason, you will owe us nothing. We put that all in writing for you. We’ll help you file you’re lawsuit.

Our No Fee Promise on Onglyza Cases

You can afford to have our great team of DPP-4 inhibitor lawyers on your side. If you choose us, it literally costs you nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a settlement
  • Phone calls are always free

Start Your Onglyza Lawsuit Claim

Our dangerous drug lawsuit lawyers will help you file your lawsuit. To get started, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call (866) 280-4722 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have claim, we will start immediately.

WARNING: There are strict time deadlines for filing lawsuit claims.